KR20110089170A - Atp-결합 카세트 수송자의 조절자 - Google Patents
Atp-결합 카세트 수송자의 조절자 Download PDFInfo
- Publication number
- KR20110089170A KR20110089170A KR1020117012767A KR20117012767A KR20110089170A KR 20110089170 A KR20110089170 A KR 20110089170A KR 1020117012767 A KR1020117012767 A KR 1020117012767A KR 20117012767 A KR20117012767 A KR 20117012767A KR 20110089170 A KR20110089170 A KR 20110089170A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- together form
- och
- ocf
- mmol
- Prior art date
Links
- 0 COC(C1(CC1)c(cc1C*)ccc1OC)=O Chemical compound COC(C1(CC1)c(cc1C*)ccc1OC)=O 0.000 description 12
- OLMKLHYYROAHHK-UHFFFAOYSA-N CC[O](C)C(CBr)[O](C)CC Chemical compound CC[O](C)C(CBr)[O](C)CC OLMKLHYYROAHHK-UHFFFAOYSA-N 0.000 description 2
- VEXWRCXKFLTYRZ-UHFFFAOYSA-N COC(C1(CC1)c(cc1)ccc1OC)=O Chemical compound COC(C1(CC1)c(cc1)ccc1OC)=O VEXWRCXKFLTYRZ-UHFFFAOYSA-N 0.000 description 2
- WNVINHKLRMAKJD-UHFFFAOYSA-N COC(C1(CC1)c(cc1N)ccc1O)=O Chemical compound COC(C1(CC1)c(cc1N)ccc1O)=O WNVINHKLRMAKJD-UHFFFAOYSA-N 0.000 description 2
- PLBDOPBECRIDKT-UHFFFAOYSA-N COc(cc(CBr)cc1)c1Cl Chemical compound COc(cc(CBr)cc1)c1Cl PLBDOPBECRIDKT-UHFFFAOYSA-N 0.000 description 2
- SMFHPCZZAAMJJO-UHFFFAOYSA-N Cc(cc1O)ccc1Cl Chemical compound Cc(cc1O)ccc1Cl SMFHPCZZAAMJJO-UHFFFAOYSA-N 0.000 description 2
- KBRLTYHUJDMMLI-UHFFFAOYSA-N Cc(cc1OC)ccc1Cl Chemical compound Cc(cc1OC)ccc1Cl KBRLTYHUJDMMLI-UHFFFAOYSA-N 0.000 description 2
- CGPPWNTVTNCHDO-UHFFFAOYSA-N Nc(c(Br)c1)ccc1[N+]([O-])=O Chemical compound Nc(c(Br)c1)ccc1[N+]([O-])=O CGPPWNTVTNCHDO-UHFFFAOYSA-N 0.000 description 2
- LOIJRUNLOIAQDI-UHFFFAOYSA-N O=Cc(cc1OCOc1c1)c1F Chemical compound O=Cc(cc1OCOc1c1)c1F LOIJRUNLOIAQDI-UHFFFAOYSA-N 0.000 description 2
- FVDKTLQPQGEMBH-UHFFFAOYSA-N CC(C)(C)C(Cc1c2)N(C(CO)CO)c1ccc2NC(C1(CC1)c(cc1)cc2c1OCO2)=O Chemical compound CC(C)(C)C(Cc1c2)N(C(CO)CO)c1ccc2NC(C1(CC1)c(cc1)cc2c1OCO2)=O FVDKTLQPQGEMBH-UHFFFAOYSA-N 0.000 description 1
- PJJDZKPYHRWZRB-UHFFFAOYSA-N CC(C)(C)C(Cc1c2)Nc1ccc2NC(C1(CC1)c(cc1)cc2c1OCO2)=O Chemical compound CC(C)(C)C(Cc1c2)Nc1ccc2NC(C1(CC1)c(cc1)cc2c1OCO2)=O PJJDZKPYHRWZRB-UHFFFAOYSA-N 0.000 description 1
- GTDBXVOQHMEUJC-UHFFFAOYSA-N CC(C)(C)c([nH]c1c2)cc1ccc2N Chemical compound CC(C)(C)c([nH]c1c2)cc1ccc2N GTDBXVOQHMEUJC-UHFFFAOYSA-N 0.000 description 1
- COQNCAZGNLRPHM-UHFFFAOYSA-N CC(C)(C)c([nH]c1c2)cc1ccc2[N+]([O-])=O Chemical compound CC(C)(C)c([nH]c1c2)cc1ccc2[N+]([O-])=O COQNCAZGNLRPHM-UHFFFAOYSA-N 0.000 description 1
- JAXOSWKMPJBKAD-UHFFFAOYSA-N CC(C)(C)c([n](CCN)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F Chemical compound CC(C)(C)c([n](CCN)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F JAXOSWKMPJBKAD-UHFFFAOYSA-N 0.000 description 1
- LVCVRAWQKGEOHD-UHFFFAOYSA-N CC(C)(C)c([n](CCNC(C)=O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(C)F)=O)c2F Chemical compound CC(C)(C)c([n](CCNC(C)=O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(C)F)=O)c2F LVCVRAWQKGEOHD-UHFFFAOYSA-N 0.000 description 1
- QLGZLFQWONZGSS-UHFFFAOYSA-N CC(C)(C)c([n](CCNC(OC(C)(C)C)=O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F Chemical compound CC(C)(C)c([n](CCNC(OC(C)(C)C)=O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F QLGZLFQWONZGSS-UHFFFAOYSA-N 0.000 description 1
- VSQCMNYBKHWBFR-UHFFFAOYSA-N CC(C)(C)c([n](CCNC(OC(C)(C)C)=O)c1c2)cc1cc(NC(C1(CC1)c1cc(OC(C)(F)F)c(C)cc1)=O)c2F Chemical compound CC(C)(C)c([n](CCNC(OC(C)(C)C)=O)c1c2)cc1cc(NC(C1(CC1)c1cc(OC(C)(F)F)c(C)cc1)=O)c2F VSQCMNYBKHWBFR-UHFFFAOYSA-N 0.000 description 1
- NDMAWDCNHUEFEM-BQYQJAHWSA-N CC(C)(C)c(cc(/C=C/[Si](C)(C)C)c(N)c1)c1[N+]([O-])=O Chemical compound CC(C)(C)c(cc(/C=C/[Si](C)(C)C)c(N)c1)c1[N+]([O-])=O NDMAWDCNHUEFEM-BQYQJAHWSA-N 0.000 description 1
- PBZKAUDHYUTEDZ-UHFFFAOYSA-N CC(C)(C)c(cc(cc[nH]1)c1c1)c1[N+]([O-])=O Chemical compound CC(C)(C)c(cc(cc[nH]1)c1c1)c1[N+]([O-])=O PBZKAUDHYUTEDZ-UHFFFAOYSA-N 0.000 description 1
- QOWLDRVCYQATFR-UHFFFAOYSA-N CC(C)(C)c1c[nH]c(cc2)c1cc2N Chemical compound CC(C)(C)c1c[nH]c(cc2)c1cc2N QOWLDRVCYQATFR-UHFFFAOYSA-N 0.000 description 1
- PDTVHDXZDIUULT-UHFFFAOYSA-N CC(C)(C)c1c[nH]c(cc2)c1cc2[N+]([O-])=O Chemical compound CC(C)(C)c1c[nH]c(cc2)c1cc2[N+]([O-])=O PDTVHDXZDIUULT-UHFFFAOYSA-N 0.000 description 1
- YOBUTELENUBOFS-UHFFFAOYSA-N CC(C)(C)c1cc(cc(cc2F)[N+]([O-])=O)c2[nH]1 Chemical compound CC(C)(C)c1cc(cc(cc2F)[N+]([O-])=O)c2[nH]1 YOBUTELENUBOFS-UHFFFAOYSA-N 0.000 description 1
- NSIJVCMKFAFADX-KRWDZBQOSA-N CC(C)(CCOC[C@H](CO)O)c([nH]c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F Chemical compound CC(C)(CCOC[C@H](CO)O)c([nH]c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F NSIJVCMKFAFADX-KRWDZBQOSA-N 0.000 description 1
- AVCNGKYYEKQPQT-UXHICEINSA-N CC(C)(CCOC[C@H](CO)O)c([n](C[C@H](CO)O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F Chemical compound CC(C)(CCOC[C@H](CO)O)c([n](C[C@H](CO)O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F AVCNGKYYEKQPQT-UXHICEINSA-N 0.000 description 1
- JTACOAQYDSHBLH-UHFFFAOYSA-N CC(C)(CO)c([nH]c1c2)cc1cc([N+]([O-])=O)c2F Chemical compound CC(C)(CO)c([nH]c1c2)cc1cc([N+]([O-])=O)c2F JTACOAQYDSHBLH-UHFFFAOYSA-N 0.000 description 1
- PAKUXAWMDNIZLQ-UHFFFAOYSA-N CC(C)(CO)c([n](CC1(COC(C)(C)O)CC1)c1c2)cc1cc([N+]([O-])=O)c2F Chemical compound CC(C)(CO)c([n](CC1(COC(C)(C)O)CC1)c1c2)cc1cc([N+]([O-])=O)c2F PAKUXAWMDNIZLQ-UHFFFAOYSA-N 0.000 description 1
- ZUFWLQWOUWSUAI-UHFFFAOYSA-N CC(C)(CO)c1cc2cc(N)ccc2[nH]1 Chemical compound CC(C)(CO)c1cc2cc(N)ccc2[nH]1 ZUFWLQWOUWSUAI-UHFFFAOYSA-N 0.000 description 1
- ASFQDNDZFGFMMP-UHFFFAOYSA-N CC(C)(OC1)OCC1=O Chemical compound CC(C)(OC1)OCC1=O ASFQDNDZFGFMMP-UHFFFAOYSA-N 0.000 description 1
- HZTUDIJSPMARPI-UHFFFAOYSA-N CC1(CC1)C#Cc1cc([N+]([O-])=O)ccc1N Chemical compound CC1(CC1)C#Cc1cc([N+]([O-])=O)ccc1N HZTUDIJSPMARPI-UHFFFAOYSA-N 0.000 description 1
- XRPBXKDBTPEKNI-UHFFFAOYSA-N CCCC(Nc(c(C#CC1(C)CC1)c1)ccc1[N+]([O-])=O)=O Chemical compound CCCC(Nc(c(C#CC1(C)CC1)c1)ccc1[N+]([O-])=O)=O XRPBXKDBTPEKNI-UHFFFAOYSA-N 0.000 description 1
- FFHCNSZYSUDCNW-UHFFFAOYSA-N CCCC(Nc(c(C#Cc1ccccc1)c1)ccc1[N+]([O-])=O)=O Chemical compound CCCC(Nc(c(C#Cc1ccccc1)c1)ccc1[N+]([O-])=O)=O FFHCNSZYSUDCNW-UHFFFAOYSA-N 0.000 description 1
- DDWTUNNTHPIJTE-UHFFFAOYSA-N CCCC(Nc(c(F)cc([N+]([O-])=O)c1)c1C#CC(C)(C)C)=O Chemical compound CCCC(Nc(c(F)cc([N+]([O-])=O)c1)c1C#CC(C)(C)C)=O DDWTUNNTHPIJTE-UHFFFAOYSA-N 0.000 description 1
- DUOLIQFKEZFZEQ-UHFFFAOYSA-N CCOC(COc1ccc(C2(CC2)C(O)=O)cc1)[O](C)CC Chemical compound CCOC(COc1ccc(C2(CC2)C(O)=O)cc1)[O](C)CC DUOLIQFKEZFZEQ-UHFFFAOYSA-N 0.000 description 1
- PEEUYOUTXIWHTF-UHFFFAOYSA-N CC[O](C)C(COc1ccc(C2(CC2)C(O)=O)cc1)[O](C)CC Chemical compound CC[O](C)C(COc1ccc(C2(CC2)C(O)=O)cc1)[O](C)CC PEEUYOUTXIWHTF-UHFFFAOYSA-N 0.000 description 1
- HPJPRDMOSBREFH-UHFFFAOYSA-N CCc(cc(CCN1)c1c1)c1[N+]([O-])=O Chemical compound CCc(cc(CCN1)c1c1)c1[N+]([O-])=O HPJPRDMOSBREFH-UHFFFAOYSA-N 0.000 description 1
- AZECJMVWQXNINT-ONEGZZNKSA-N CN(C)/C=C/c(c([N+]([O-])=O)c1)cc(C(F)(F)F)c1[N+]([O-])=O Chemical compound CN(C)/C=C/c(c([N+]([O-])=O)c1)cc(C(F)(F)F)c1[N+]([O-])=O AZECJMVWQXNINT-ONEGZZNKSA-N 0.000 description 1
- VWBFDRBGHCPJFL-UHFFFAOYSA-N COC(C1(CC1)c(cc1)ccc1O)=O Chemical compound COC(C1(CC1)c(cc1)ccc1O)=O VWBFDRBGHCPJFL-UHFFFAOYSA-N 0.000 description 1
- JCFJWVBZAGQDTR-UHFFFAOYSA-N COC(C1(CC1)c(cc1CCl)ccc1OC)=O Chemical compound COC(C1(CC1)c(cc1CCl)ccc1OC)=O JCFJWVBZAGQDTR-UHFFFAOYSA-N 0.000 description 1
- LRGVLVWFDGGWKQ-UHFFFAOYSA-N COC(C1(CC1)c(cc1CO)ccc1OC)=O Chemical compound COC(C1(CC1)c(cc1CO)ccc1OC)=O LRGVLVWFDGGWKQ-UHFFFAOYSA-N 0.000 description 1
- XWAKOHDDAWTROD-UHFFFAOYSA-N COC(C1(CC1)c1ccc2OCCCc2c1)=O Chemical compound COC(C1(CC1)c1ccc2OCCCc2c1)=O XWAKOHDDAWTROD-UHFFFAOYSA-N 0.000 description 1
- JVXXBYWGNKPWJW-UHFFFAOYSA-N COC(CCCCc1ccc2[o]cnc2c1)=O Chemical compound COC(CCCCc1ccc2[o]cnc2c1)=O JVXXBYWGNKPWJW-UHFFFAOYSA-N 0.000 description 1
- FYWQFFZDUYPFES-UHFFFAOYSA-N COCc1ccc2OCCOc2c1 Chemical compound COCc1ccc2OCCOc2c1 FYWQFFZDUYPFES-UHFFFAOYSA-N 0.000 description 1
- XOSGKJSNVLAMGY-UHFFFAOYSA-N COc1cc(CC#N)ccc1Cl Chemical compound COc1cc(CC#N)ccc1Cl XOSGKJSNVLAMGY-UHFFFAOYSA-N 0.000 description 1
- KZWVOCABQPZOOJ-UHFFFAOYSA-N COc1ccc(C2(CC2)C(C=O)=O)cc1 Chemical compound COc1ccc(C2(CC2)C(C=O)=O)cc1 KZWVOCABQPZOOJ-UHFFFAOYSA-N 0.000 description 1
- WCPFQQHADRJANG-UHFFFAOYSA-N COc1ccc(C2(CC2)C(O)=O)cc1 Chemical compound COc1ccc(C2(CC2)C(O)=O)cc1 WCPFQQHADRJANG-UHFFFAOYSA-N 0.000 description 1
- HQBNLJOWTODEPR-UHFFFAOYSA-N COc1ccc(C2(CC2)C(O)=O)cc1CO Chemical compound COc1ccc(C2(CC2)C(O)=O)cc1CO HQBNLJOWTODEPR-UHFFFAOYSA-N 0.000 description 1
- CBUIRFONVKDQGP-UHFFFAOYSA-N C[O](C1)C1C(C1(CC1)c1ccc2[o]cnc2c1)=O Chemical compound C[O](C1)C1C(C1(CC1)c1ccc2[o]cnc2c1)=O CBUIRFONVKDQGP-UHFFFAOYSA-N 0.000 description 1
- SUSQOBVLVYHIEX-UHFFFAOYSA-N N#CCc1ccccc1 Chemical compound N#CCc1ccccc1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N Nc(cc1)ccc1[N+]([O-])=O Chemical compound Nc(cc1)ccc1[N+]([O-])=O TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- INAPHBAYFQAFEQ-UHFFFAOYSA-N Nc(ccc([N+]([O-])=O)c1)c1C#Cc1ccccc1 Chemical compound Nc(ccc([N+]([O-])=O)c1)c1C#Cc1ccccc1 INAPHBAYFQAFEQ-UHFFFAOYSA-N 0.000 description 1
- QQZNJABYWKNVPQ-UHFFFAOYSA-N Nc1c(C(F)(F)F)cc(cc[nH]2)c2c1 Chemical compound Nc1c(C(F)(F)F)cc(cc[nH]2)c2c1 QQZNJABYWKNVPQ-UHFFFAOYSA-N 0.000 description 1
- HLADYMRXHXVWDP-UHFFFAOYSA-N OC(C1(CC1)c(cc1)cc2c1OCCC2)=O Chemical compound OC(C1(CC1)c(cc1)cc2c1OCCC2)=O HLADYMRXHXVWDP-UHFFFAOYSA-N 0.000 description 1
- RRWKJVZZARHFPB-UHFFFAOYSA-N OC(C1(CC1)c1ccc2[o]ccc2c1)=O Chemical compound OC(C1(CC1)c1ccc2[o]ccc2c1)=O RRWKJVZZARHFPB-UHFFFAOYSA-N 0.000 description 1
- MRBYETGWOTWPIY-UHFFFAOYSA-N OC(C1(CC1)c1ccc2[o]cnc2c1)=O Chemical compound OC(C1(CC1)c1ccc2[o]cnc2c1)=O MRBYETGWOTWPIY-UHFFFAOYSA-N 0.000 description 1
- OOKJYFVPBPNDNF-UHFFFAOYSA-N OCc(cc1OCOc1c1)c1F Chemical compound OCc(cc1OCOc1c1)c1F OOKJYFVPBPNDNF-UHFFFAOYSA-N 0.000 description 1
- FXDGVLXBUNQEQK-UHFFFAOYSA-N Oc(c(O)c1)cc(C=O)c1F Chemical compound Oc(c(O)c1)cc(C=O)c1F FXDGVLXBUNQEQK-UHFFFAOYSA-N 0.000 description 1
- DBPZCGJRCAALLW-UHFFFAOYSA-N Oc(cc1)cc2c1OCCO2 Chemical compound Oc(cc1)cc2c1OCCO2 DBPZCGJRCAALLW-UHFFFAOYSA-N 0.000 description 1
- UNJRQDPTLDVHOR-UHFFFAOYSA-N [O-][N+](c1ccc2[nH]c(-c3ccccc3)cc2c1)=O Chemical compound [O-][N+](c1ccc2[nH]c(-c3ccccc3)cc2c1)=O UNJRQDPTLDVHOR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11215208P | 2008-11-06 | 2008-11-06 | |
US61/112,152 | 2008-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110089170A true KR20110089170A (ko) | 2011-08-04 |
Family
ID=42153560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117012767A KR20110089170A (ko) | 2008-11-06 | 2009-11-06 | Atp-결합 카세트 수송자의 조절자 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2362874A2 (fr) |
JP (2) | JP2012508246A (fr) |
KR (1) | KR20110089170A (fr) |
CN (2) | CN102272128A (fr) |
AU (1) | AU2009313409A1 (fr) |
BR (1) | BRPI0921234B8 (fr) |
CA (2) | CA2742980A1 (fr) |
CL (1) | CL2011001004A1 (fr) |
HK (1) | HK1226076A1 (fr) |
IL (2) | IL212727A (fr) |
MX (1) | MX2011004834A (fr) |
NZ (2) | NZ592693A (fr) |
RU (2) | RU2011122646A (fr) |
SG (1) | SG10201501168RA (fr) |
UA (2) | UA104876C2 (fr) |
WO (1) | WO2010054138A2 (fr) |
ZA (1) | ZA201103856B (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
EP3696174A1 (fr) | 2005-11-08 | 2020-08-19 | Vertex Pharmaceuticals Incorporated | Modulateurs hétérocycliques de transporteurs de cassette à liaison atp |
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
SI2674428T1 (sl) | 2006-04-07 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Modulatorji transporterjev atp-vezavne kasete |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
CN101687842B (zh) | 2007-05-09 | 2013-03-06 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
LT2639223T (lt) | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
KR101559963B1 (ko) * | 2008-11-06 | 2015-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
CA2794559C (fr) * | 2010-03-25 | 2019-07-23 | Vertex Pharmaceuticals Incorporated | Formes solides de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide |
WO2011127241A2 (fr) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration |
AU2011242454A1 (en) * | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CN103038214B (zh) | 2010-04-22 | 2015-09-30 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
NZ603044A (en) * | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
EP3138563A1 (fr) * | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Compositions pharmaceutiques et leurs administrations |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
AU2011293658B2 (en) | 2010-08-23 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
CA2878057A1 (fr) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Compositions pharmaceutiques de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropane-carboxamide et leur administration |
TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
EP2970468B1 (fr) | 2013-03-13 | 2021-07-07 | Novartis AG | Molécules de liaison à notch2 pour le traitement de maladies respiratoires |
KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
EP2878339A1 (fr) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | Antagonistes SIP3 |
AR099336A1 (es) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
EP2932966A1 (fr) | 2014-04-16 | 2015-10-21 | Novartis AG | Inhibiteurs de la gamma sécrétase pour traiter des maladies respiratoires |
GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
CN107110831B (zh) | 2014-11-18 | 2020-02-21 | 弗特克斯药品有限公司 | 进行高通量试验高效液相色谱的方法 |
US10167278B2 (en) | 2014-12-31 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
SG10201913595YA (en) | 2016-09-30 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2018107100A1 (fr) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
CA3066084A1 (fr) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methodes de traitement de la fibrose kystique |
MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
CA3078893A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
WO2019113476A2 (fr) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
EP3774825A1 (fr) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
CN109651160B (zh) * | 2019-01-25 | 2021-08-13 | 上海应用技术大学 | 一种催化苯乙炔氢胺化反应制备烯胺类化合物的方法 |
CN111763198B (zh) * | 2019-04-01 | 2021-09-07 | 新发药业有限公司 | 一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
CA3150162A1 (fr) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
CN112624956A (zh) * | 2019-10-08 | 2021-04-09 | 兰州大学 | 3-吲哚磺酸衍生物新型制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
EP1554271A1 (fr) * | 2002-10-15 | 2005-07-20 | Rigel Pharmaceuticals, Inc. | Indoles substitues et leur utilisation en tant qu'inhibiteurs du virus de l'hepatite c (vhc) |
KR20060088537A (ko) * | 2003-09-06 | 2006-08-04 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절자 |
NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
SI2674428T1 (sl) * | 2006-04-07 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Modulatorji transporterjev atp-vezavne kasete |
UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
KR101559963B1 (ko) * | 2008-11-06 | 2015-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
AU2010310449A1 (en) * | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
-
2008
- 2008-11-12 UA UAA201106975A patent/UA104876C2/uk unknown
-
2009
- 2009-06-11 UA UAA201106976A patent/UA110192C2/uk unknown
- 2009-11-06 AU AU2009313409A patent/AU2009313409A1/en not_active Abandoned
- 2009-11-06 KR KR1020117012767A patent/KR20110089170A/ko not_active Application Discontinuation
- 2009-11-06 WO PCT/US2009/063475 patent/WO2010054138A2/fr active Application Filing
- 2009-11-06 MX MX2011004834A patent/MX2011004834A/es active IP Right Grant
- 2009-11-06 NZ NZ592693A patent/NZ592693A/xx not_active IP Right Cessation
- 2009-11-06 CA CA2742980A patent/CA2742980A1/fr not_active Abandoned
- 2009-11-06 CN CN2009801539702A patent/CN102272128A/zh active Pending
- 2009-11-06 RU RU2011122646/04A patent/RU2011122646A/ru not_active Application Discontinuation
- 2009-11-06 EP EP09795592A patent/EP2362874A2/fr not_active Withdrawn
- 2009-11-06 SG SG10201501168RA patent/SG10201501168RA/en unknown
- 2009-11-06 BR BRPI0921234A patent/BRPI0921234B8/pt active IP Right Grant
- 2009-11-06 NZ NZ610972A patent/NZ610972A/en not_active IP Right Cessation
- 2009-11-06 CN CN201610012624.4A patent/CN105693701B/zh active Active
- 2009-11-06 JP JP2011535676A patent/JP2012508246A/ja not_active Withdrawn
- 2009-11-06 CA CA2948104A patent/CA2948104C/fr active Active
-
2011
- 2011-05-05 IL IL212727A patent/IL212727A/en active IP Right Grant
- 2011-05-05 CL CL2011001004A patent/CL2011001004A1/es unknown
- 2011-05-25 ZA ZA2011/03856A patent/ZA201103856B/en unknown
-
2012
- 2012-06-01 HK HK16114548A patent/HK1226076A1/zh unknown
-
2014
- 2014-08-07 IL IL233996A patent/IL233996A/en active IP Right Grant
- 2014-09-30 RU RU2014139599A patent/RU2014139599A/ru not_active Application Discontinuation
- 2014-11-25 JP JP2014237756A patent/JP2015061860A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BRPI0921234B1 (pt) | 2021-06-22 |
IL212727A (en) | 2014-08-31 |
RU2011122646A (ru) | 2012-12-20 |
NZ592693A (en) | 2013-05-31 |
WO2010054138A3 (fr) | 2010-11-11 |
HK1226076A1 (zh) | 2017-09-22 |
IL233996A0 (en) | 2014-09-30 |
CL2011001004A1 (es) | 2012-03-16 |
CA2948104A1 (fr) | 2010-05-14 |
RU2014139599A (ru) | 2016-04-20 |
NZ610972A (en) | 2014-11-28 |
WO2010054138A2 (fr) | 2010-05-14 |
JP2015061860A (ja) | 2015-04-02 |
IL233996A (en) | 2015-09-24 |
EP2362874A2 (fr) | 2011-09-07 |
JP2012508246A (ja) | 2012-04-05 |
AU2009313409A1 (en) | 2010-05-14 |
UA110192C2 (uk) | 2015-12-10 |
CN105693701B (zh) | 2021-08-10 |
CA2742980A1 (fr) | 2010-05-14 |
BRPI0921234B8 (pt) | 2022-07-19 |
CN105693701A (zh) | 2016-06-22 |
IL212727A0 (en) | 2011-07-31 |
UA104876C2 (uk) | 2014-03-25 |
SG10201501168RA (en) | 2015-04-29 |
ZA201103856B (en) | 2012-02-29 |
CN102272128A (zh) | 2011-12-07 |
MX2011004834A (es) | 2011-07-28 |
CA2948104C (fr) | 2017-09-12 |
BRPI0921234A2 (pt) | 2016-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10987348B2 (en) | Modulators of ATP-binding cassette transporters | |
US10022352B2 (en) | Modulators of ATP-binding cassette transporters | |
EP2674428B1 (fr) | Modulateurs des transporteurs de cassettes de liaison de l'ATP | |
KR20110089170A (ko) | Atp-결합 카세트 수송자의 조절자 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |